Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. 1996

R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
Veterinary Medical Teaching Hospital, University of California, Davis, USA.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D000077339 Leflunomide An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. Arava,HWA 486,HWA-486,N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide,SU101,HWA486

Related Publications

R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
January 2002, Veterinary surgery : VS,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
January 2001, Transplantation proceedings,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
December 1995, Transplantation proceedings,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
April 2003, Transplantation,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
January 2007, Veterinary surgery : VS,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
April 1984, Diseases of the colon and rectum,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
May 1988, Transplantation,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
April 1996, Transplantation proceedings,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
December 1989, Transplantation,
R A Lirtzman, and C R Gregory, and R E Levitski, and S M Griffey, and L S Yeh, and J D Patz, and R E Morris
October 1988, Transplantation proceedings,
Copied contents to your clipboard!